This document is a published US patent application (US20260085100A1) from The Wistar Institute of Anatomy and Biology, filed on May 14, 2025, and published on March 26, 2026. It describes methods for manufacturing individualized vaccines using nucleic acid molecules that encode neoantigens specific to tumor antigens. The application also covers compositions with coding regions for neoantigens and methods for immunizing subjects.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it signals potential future developments in vaccine and immunotherapy technology. Companies involved in pharmaceutical manufacturing, biotechnology, and healthcare research should be aware of this disclosure as it may influence future product development and intellectual property landscapes in the field of oncology and vaccine development.